New Mexico Administrative Code › Title 16 - OCCUPATIONAL AND PROFESSIONAL LICENSING › Chapter 5 - DENTISTRY (DENTISTS, DENTAL HYGIENISTS, ETC.) › Part 57 - MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES › Section 16.5.57.7 - DEFINITIONS

Current through Register Vol. 35, No. 13, July 16, 2024
A.
"Addiction"
means a neurobehavioral syndrome with genetic and
				environmental influences that result in psychological dependence on the use of
				substances for their psychic effects. It is characterized by behaviors that
				include one or more of the following: impaired control over drug use;
				compulsive use; continued use despite harm; and craving.
B.
"Accepted guideline"
means
				the most current clinical pain management guideline developed by the American
				geriatrics society or the American pain society or a clinical pain management
				guideline based on evidence and expert opinion that has been accepted by the
				New Mexico medical board.
C.
"Acute pain"
means the normal, predicted physiological response to
				a noxious chemical or thermal or mechanical stimulus, typically associated with
				invasive procedures, trauma or disease and is generally time-limited.
D.
"Chronic pain"
means pain
				that persists after reasonable dental efforts have been made to relieve the
				pain or its cause and that continues, either continously or episodically, for
				longer than three consective months "chronic pain" does not, for purpose of the
				Pain Relief Act requirements, include pain associated with a terminal condition
				or with a progressive disease that, in the normal course of progression, may
				reasonably be expected to result in a terminal condition.
E.
"Clinical expert"
means a
				person who, by reason of specialized education or substantial relevant
				experience in pain management, has knowledge regarding current standards,
				practices and guidelines.
F.
"Drug abuser"
means a person who takes a drugs or controlled
				substances for other than legitimate dental purposes.
G.
"Opioid analgesic"
means
				buprenorphine, butorphanol, codeine, hydrocodone, hydromorphine, levorphanol,
				meperidine, methadone, morphine, nalbuphone, oxycodone, ocymorphone,
				pentazocine and propoxyphene as well as their brand names, isomers and
				combinations.
H.
"Opioid
				antagonist"
means a drug approved by the federal food and drug
				administration that when administered negates or neutralizes in whole or in
				part the pharmacological effects of an opioid analgesic in the body, including
				naloxone and such other medications approved by the board of pharmacy for the
				reversal of opioid analgesic overdoses.
I.
"Pain"
means acute or chronic
				pain or both.
J.
"Physical
				dependence"
means a state of adaptation that is manifested by a
				drug-specific withdrawal syndrome that can be produced by abrupt cessation,
				rapid dose reduction, decreasing blood level of the drug, administration of an
				antagonist, or a combination of these.
K.
"Prescription monitoring program
				(PMP)"
means a centralized system to collect, monitor, and analyze
				electronically, for controlled substances, prescribing and dispensing data
				submitted by pharmacies and dispensing practitioners. The data is used to
				support efforts in education, research, enforcement, and abuse
				prevention.
L.
"Therapeutic
				purpose"
means the use of pharmaceutical and non-pharmaceutical dental
				treatment that conforms substantially to accepted guidelines for pain
				management.
M.
"Tolerance"
means a state of adaptation in which exposure to a drug
				induces changes that result in a diminution of one or more of the drug's
				effects over time.